NetworkNewsBreaks – Catalyst Pharmaceuticals (NASDAQ: CPRX) Shares Rally on Positive Data from Investigator-Sponsored Trial of Firdapse®
Shares of Catalyst Pharmaceuticals (NASDAQ: CPRX) are up more than 40% this morning following the company’s release of positive top-line results from the investigator-sponsored trial evaluating Firdapse® as a treatment for myasthenia gravis (MG) patients with anti-MuSK antibodies (MuSK-MG). MuSK-MG is an extremely rare form of MG with no FDA approved therapies currently available. Both of the co-primary efficacy endpoints of change from baseline (CFB) in total quantitative myasthenia gravis score and CFB in total myasthenia gravis activities of daily living score were statistically and clinically significant in this trial. Several secondary efficacy measures also achieved statistical significance, and the…